how-to-patent-in-europe-epo Designs Related Topics 
The IPKat
MAY 31, 2023
The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. 2021 ), the Supreme Court found Amgen's function and epitope defined PCSK9 antibody patents to lack enablement ( Amgen Inc v Sanofi, No. The patents in dispute in Amgen v Sanofi defined a class of antibodies by their function and epitope.
SpicyIP
FEBRUARY 10, 2024
The findings of this short judgement have possible significant implications on the jurisprudence regarding 3(k) and business methods in the Patent Act. The Controller of Patents and Designs in July which had rejected a patent application for being primarily a claim to business method. extracted in Para 5 of judgement).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Intepat
DECEMBER 24, 2021
It is still rethinking how to approach and solve challenges in a wide range of sectors. The question then becomes whether these AI-generated inventions are patentable under present patent law. The question then becomes whether these AI-generated inventions are patentable under present patent law. BACKGROUND.
The IPKat
MARCH 6, 2022
with specific examples of how well-known companies are filing trade mark applications related to the use of tokens in virtual environments. with specific examples of how well-known companies are filing trade mark applications related to the use of tokens in virtual environments. Meanwhile, in Japan, Apple Inc.
LexBlog IP
JULY 26, 2022
Over the past two decades or so, the number of major jurisdictions offering some form of general ‘grace period’ for filing of patent applications has grown significantly. compare the perceived level of legal uncertainty that would be generated by the introduction of a grace period under different design options.
The IPKat
DECEMBER 28, 2021
This year also saw release of the EBA decision on double-patenting and a new referral on the thorny issue of plausibility and post-published evidence. As the year draws to a close, we also have news of a new referral to the EBA on the EPO's co-applicant approach to priority. Double-trouble ??
The IPKat
NOVEMBER 6, 2023
In the recent UK decision Astellas v Teva [2023] EWHC 2571 (Pat) Mr Justice Mellor in the High Court considered sufficiency, inventive step and infringement of Astellas' formulation patent for mirabegron. The decision also deviates from EPO practice on sufficiency and the inventive step of selection inventions.
Expert insights. Personalized for you.
93 
Let's personalize your content